Medline (NASDAQ:MDLN) Coverage Initiated by Analysts at Citigroup

Citigroup began coverage on shares of Medline (NASDAQ:MDLN) in a research report sent to investors on Wednesday, MarketBeat reports. The brokerage issued a buy rating and a $60.00 price target on the stock.

Several other analysts have also recently commented on MDLN. Jefferies Financial Group assumed coverage on shares of Medline in a research note on Monday, January 12th. They issued a “buy” rating and a $50.00 price target on the stock. Stifel Nicolaus set a $55.00 price objective on Medline in a research report on Wednesday, February 25th. Truist Financial initiated coverage on Medline in a report on Monday, January 12th. They issued a “buy” rating and a $52.00 target price on the stock. Morgan Stanley increased their price target on Medline from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. Finally, Royal Bank Of Canada raised their price target on Medline from $47.00 to $53.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $50.62.

Medline Stock Down 1.1%

MDLN stock opened at $42.39 on Wednesday. Medline has a 1-year low of $34.89 and a 1-year high of $50.88. The business has a 50 day simple moving average of $44.62.

Medline (NASDAQ:MDLN) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.25). The firm had revenue of $7.79 billion for the quarter, compared to analysts’ expectations of $7.52 billion. The company’s revenue was up 14.8% on a year-over-year basis.

Insider Activity

In related news, Director Charles N. Mills acquired 2,579,310 shares of Medline stock in a transaction on Thursday, December 18th. The shares were bought at an average cost of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the purchase, the director directly owned 2,441,379 shares of the company’s stock, valued at $70,799,991. The trade was a -1,870.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Andrew J. Mills acquired 2,586,206 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were bought at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the completion of the transaction, the director owned 2,586,206 shares of the company’s stock, valued at approximately $74,999,974. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Hedge Funds Weigh In On Medline

Several large investors have recently modified their holdings of MDLN. Corient Private Wealth LLC bought a new stake in Medline in the fourth quarter worth $306,000. Kera Capital Partners Inc. bought a new position in Medline during the fourth quarter valued at $3,785,000. Virtu Financial LLC purchased a new stake in shares of Medline in the fourth quarter valued at $2,243,000. T. Rowe Price Investment Management Inc. bought a new stake in shares of Medline in the 4th quarter worth about $298,461,000. Finally, Invesco Ltd. bought a new stake in shares of Medline in the 4th quarter worth about $106,239,000.

Key Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Citigroup initiated coverage with a “Buy” and $60 price target, signaling sizeable upside from current levels and bringing fresh institutional support. Citigroup initiates coverage
• Positive Sentiment: JPMorgan raised its price target to $53 and kept an “Overweight” stance, adding incremental analyst conviction. JPMorgan raises price target
• Positive Sentiment: BTIG reiterated a Buy rating and Tigress Financial (Tigress) reiterated bullish commentary, reinforcing the buy-side narrative among sell‑side firms. BTIG reiterates Buy
• Positive Sentiment: Medline broke ground on a 1.2M sq. ft. distribution center in Midlothian, TX — a capital/operational expansion that supports revenue growth and supply‑chain reach over the medium term. Groundbreaking announcement
• Neutral Sentiment: The secondary offering closed under the registration statement process and was fully underwritten — a procedural completion that formalizes the new publicly tradable supply. Secondary offering close (procedural)
• Negative Sentiment: Large secondary sale: 86.25M Class A shares were sold at $41.00 by selling stockholders (including PE affiliates). Although Medline received no proceeds, the transaction increases public float and can apply downward pressure on the share price. Secondary offering details
• Negative Sentiment: Recent quarter: Medline missed EPS estimates (reported -$0.01 vs. ~$0.24 consensus) despite a revenue beat — an earnings surprise that remains a near‑term performance headwind and likely part of today’s selling pressure.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.